Agents to treat BRAF-mutant lung cancer
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2019-03-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://drugsincontext.com/agents-to-treat-braf-mutant-lung-cancer |